This registrational trial represents a major step toward potential approval and commercialization of HMPL-760. Traders should monitor enrollment progress, upcoming interim data, and any future FDA/EMA trial initiation. The absence of partnership or dilution risk (HUTCHMED retains full rights) enhances equity upside.
Price Chart
Executive Summary
HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibitor, in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial follows promising Phase II results showing improved response and survival outcomes, positioning HMPL-760 as a potential best-in-class therapy targeting both wild-type and C481S-mutated BTK.
Key Facts
- HUTCHMED initiated a registrational Phase III trial of HMPL-760 in combination with R-GemOx for relapsed/refractory DLBCL in China.
- First patient dosed on March 20, 2026; trial is randomized, double-blind, and placebo-controlled.
- Primary endpoints are progression-free survival (PFS) and overall survival (OS); trial will enroll ~240 patients.
- Phase II data (NCT06601504) showed improved ORR, CRR, PFS, and OS with manageable safety profile.
- HMPL-760 is a non-covalent, reversible, third-generation BTK inhibitor active against C481S-mutated BTK, a key resistance mechanism.
- HUTCHMED retains global rights to HMPL-760, enabling full commercial upside.
Financial Impact
High long-term value potential if approved, given DLBCL's prevalence (~81,000 new NHL cases annually in China) and lack of effective therapies for relapsed/refractory patients.
Risk Factors
- Clinical trial may fail to confirm Phase II efficacy, particularly in PFS and OS endpoints.
- Safety issues could emerge in larger trial population.
- Regulatory delays or requirements for additional studies could prolong path to approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260096 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access